| Literature DB >> 34989956 |
Sahar Zaidi1, Tulika Bhardwaj2, Pallavi Somvanshi2,3, Asad U Khan4.
Abstract
The aim of the present study, is to identify potential targets against the highly pathogenic bacteria Streptococcus mutans that causes dental caries as well as the deadly infection of endocarditis. The powerful and highly sensitive technique of liquid chromatography-mass spectrometry (LC-MS/MS) identified 321 proteins of S. mutans when grown under stressful conditions induced by the antibiotic bacitracin. These 321 proteins were subjected to the insilico method of subtractive proteomics to screen out potential targets by utilizing different analyses like CD-HIT, non-homologous sequence screening, KEGG pathway, essentiality screening, gut-flora non-homology, and codon usage analysis. A database of essential proteins was employed to find sequence homology of non-paralogous proteins to determine proteins which are essential for bacterial survival. Cellular localization analysis of the selected proteins was done to localize them inside the cell along with physico-chemical characterization and druggability analysis. Using computational tools, 22 proteins out of 321, that are functionally distinguishable from their human counterparts and passed the criterion of a potential therapeutic candidate were identified. The selected proteins comprise central energy metabolic proteins, virulence factors, proteins of the sortase family, and essentiality factors. The presented analyses identified proteins of the sortase family, which appear as key therapeutic targets against caries infection. These proteins regulate a number of virulence factors, thus can be simultaneously inhibited to obstruct multiple virulence pathways.Entities:
Keywords: Bacitracin; Essentiality analysis; LC–MS; S. mutans; Subtractive proteomics
Mesh:
Substances:
Year: 2022 PMID: 34989956 PMCID: PMC8733428 DOI: 10.1007/s10930-021-10038-1
Source DB: PubMed Journal: Protein J ISSN: 1572-3887 Impact factor: 4.000
Fig. 1KEGG Pathway analysis identifies 21 pathways unique to bacteria only. KAAS webserver encodes majority of the selected proteins involved in the biosynthesis of antibiotics (19%) followed by secondary metabolites biosynthesis (12%) and lysine metabolism (11%)
List of 22 potential target, their function, location and codon adaptation index
| S.No. | Potential targets | Function | Location | Codon adaptation index |
|---|---|---|---|---|
| 1 | Glucose-6-phosphate isomerase | Glycolysis Biosynthesis of antibiotics Biosynthesis of secondary metabolites | Cytoplasmic | 0.76 |
| 2 | 4-Hydroxy-tetrahydrodipicolinate reductase | Lysine biosynthesis Monobactam biosynthesis | Cytoplasmic | 0.80 |
| 3 | Glycogen synthase | Biosynthesis of secondary metabolites | Cytoplasmic | 0.71 |
| 4 | Glucan-binding protein GbpC | Bacterial adherence and extracellular polymeric substance (EPS) synthesis | Extracellular | 0.75 |
| 5 | Cell surface antigen SpaP | Adherence | Extracellular | 0.91 |
| 6 | Thiol peroxidase | H2O2 Receptor and Redox-Transducer | Cytoplasmic | 0.87 |
| 7 | Levansucrase | Two-component system Starch and sucrose metabolism | Extracellular | 0.89 |
| 8 | Phospho-2-dehydro-3-deoxyheptonate aldolase | Phenylalanine, tyrosine and tryptophan biosynthesis Biosynthesis of secondary metabolites | Cytoplasmic | 0.79 |
| 9 | ATP synthase F0F1 subunit alpha | Oxidative phosphorylation | Cytoplasmic | 0.92 |
| 10 | ATP synthase F0F1 subunit beta | Oxidative phosphorylation | Cytoplasmic | 0.87 |
| 11 | Glucosyltransferase-SI (GtfC) | Two-component system | Extracellular | 0.88 |
| 12 | Glucosyltransferase-I (GtfB) | Two-component system | Extracellular | 0.89 |
| 13 | secreted antigen GbpB/SagA | Peptidoglycan biosynthesis and degradation proteins | Extracellular | 0.92 |
| 14 | Formate acetyltransferase/ Pyruvate formate–lyase | Pyruvate and butanoate metabolism | Cytoplasmic | 0.93 |
| 15 | Fructose-1,6-biphosphate aldolase | Glycolysis | Cytoplasmic | 0.80 |
| 16 | Endolytic murein transglycosylase | Terminates nascent peptidoglycan synthesis | Extracellular | 0.88 |
| 17 | L-lactate dehydrogenase | Glycolysis / Gluconeogenesis Cysteine and methionine metabolism | Cytoplasmic | 0.82 |
| 18 | Ketol-acid reductoisomerase | Pantothenate and CoA biosynthesis 2-Oxocarboxylic acid metabolism | Cytoplasmic | 0.92 |
| 19 | Aspartate-semialdehyde dehydrogenase | Lysine biosynthesis Monobactam biosynthesis | Cytoplasmic | 0.97 |
| 20 | Enolase | Glycolysis Methane metabolism | Cytoplasmic | 0.85 |
| 21 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1 | Peptidoglycan biosynthesis | Cytoplasmic | 0.95 |
| 22 | ATP-dependent protease ClpE | Genetic information processing | Cytoplasmic | 0.79 |
Details of the proteome subtractive and qualitative characterization methods
| Module | Proteome subtraction methods | Softwares | Total dataset | Selected | Excluded |
|---|---|---|---|---|---|
| 1 | Total proteome content | CD-Hit | 321 | 299 | 22 |
| Non-homology analysis | BLASTp | 299 | 151 | 148 | |
| 2 | Essentiality analysis | DEG | 151 | 67 | 84 |
| Pathway analysis | KEGG | 67 | 45 | 22 | |
| Gut-flora non-homology analysis | BLASTp | 45 | 22 | 23 | |
| Codon usage analysis | CAI | ALL | – | ||
| 3 | Subcellular localization analysis | CELLO | 22 | 22 | – |
| Physicochemical characterization | ProtParam | 22 | 22 | – | |
| Druggability analysis | DrugBank | 22 | 22 | – | |
List of thephysico-chemical properties of selected potential targets
| Potential drug targets | Number of Amino acids | Molecular weight | Isoelectric Point | negatively charged residues | positively charged residues | aliphatic index | Instability index | Extinction coefficient (M−1 cm−1) | GRAVY | Nature |
|---|---|---|---|---|---|---|---|---|---|---|
| Glucose-6-phosphate isomerase | 449 | 49,421.66 | 4.84 | 63 | 45 | 88.69 | 27.26 | 54,780 | − 0.232 | Stable |
| 4-Hydroxy-tetrahydrodipicolinate reductase | 255 | 27,804.82 | 5.07 | 39 | 27 | 69.51 | 20.48 | 239,060 | − 0.063 | Stable |
| Glycogen synthase | 476 | 54,311.80 | 5.69 | 45 | 36 | 87.01 | 32.11 | 7572 | − 0.287 | Stable |
| Glucan-binding protein GbpC | 583 | 63,349.90 | 6.75 | 20 | 20 | 104.93 | 25.67 | 4576 | 0.079 | Stable |
| Cell surface antigen SpaP | 1562 | 169,971.93 | 5.3 | 35 | 31 | 104.52 | 23.72 | 16,008 | − 0.223 | Stable |
| Thiol peroxidase | 161 | 17,552.71 | 5.08 | 36 | 31 | 122.83 | 27.03 | 24,535 | − 0.061 | Stable |
| Levansucrase | 795 | 87,384.68 | 5.8 | 27 | 22 | 93.44 | 21.92 | 13,076 | − 0.114 | Stable |
| Phospho-2-dehydro-3-deoxyheptonate aldolase | 343 | 38,718.65 | 5.53 | 43 | 42 | 77.33 | 39.84 | 22,256 | − 0.455 | Stable |
| ATP synthase F0F1 subunit alpha | 501 | 54,372.84 | 5.42 | 28 | 15 | 7450 | 47.87 | 19,878 | − 0.094 | Unstable |
| ATP synthase F0F1 subunit beta | 689 | 75,218.11 | 4.88 | 45 | 30 | 101.02 | 40.2 | 22,045 | − 0.473 | Unstable |
| Glucosyltransferase-SI | 1455 | 162,966.24 | 5.28 | 41 | 36 | 100.1 | 33.5 | 14,900 | − 0.151 | Stable |
| Glucosyltransferase-I | 1476 | 165,846.81 | 5.09 | 68 | 53 | 103.68 | 30.32 | 25,245 | − 0.16 | Stable |
| secreted antigen GbpB/SagA | 431 | 44,620.42 | 9.46 | 66 | 64 | 94.65 | 27.18 | 17,880 | − 0.219 | Stable |
| Formate acetyltransferase | 775 | 87,605.80 | 5.27 | 49 | 38 | 92.7 | 21.62 | 26,860 | − 0.321 | Stable |
| Fructose-1,6-biphosphate aldolase | 293 | 31,425.80 | 5.46 | 32 | 26 | 99.96 | 31.78 | 13,535 | 0.007 | Stable |
| Endolytic murein transglycosylase | 614 | 68,543.36 | 6.61 | 37 | 36 | 102.59 | 20.19 | 16,180 | − 0.226 | Stable |
| 328 | 35,245.09 | 5.85 | 33 | 31 | 96.28 | 25.97 | 14,440 | − 0.089 | Stable | |
| Ketol-acid reducto isomerase | 340 | 37,285.33 | 5.53 | 68 | 56 | 92.79 | 27.1 | 37,650 | − 0.277 | Stable |
| Aspartate-semialdehyde dehydrogenase | 358 | 38,903.31 | 6.21 | 45 | 41 | 89.54 | 29.85 | 23,452 | − 0.365 | Stable |
| Enolase | 432 | 46,857.61 | 9.32 | 56 | 92 | 87.62 | 38.9 | 47,655 | − 0.555 | Stable |
| UDP-N-acetylglucosamine 1-carboxyvinyl-transferase 1 | 423 | 45,616.65 | 4.95 | 45 | 33 | 92.46 | 34.55 | 11,564 | − 0.51 | Stable |
| ATP-dependent protease ClpE | 753 | 83,733.90 | 5.59 | 31 | 55 | 100.34 | 22.87 | 17,886 | − 0.195 | Stable |
Listing of FDA approved drugs (Drug names, DrugBank ID) for the 22 screened potential drug targets
| S.No. | Drug target | Drug name | DrugBank ID |
|---|---|---|---|
| 1 | Glucose-6-phosphate isomerase | Vitafol-one Artenimol | DB09130 DB11638 |
| 2 | 4-Hydroxy-tetrahydrodipicolinate reductase | Dipicolinic acid | DB04267 |
| 3 | Glycogen synthase | Valproate Tideglusib | DB00313 DB12129 |
| 4 | Glucan-binding protein GbpC | Eraxis Vfend | DB00362 DB00582 |
| 5 | cell surface antigen SpaP | Gleevec | DB00619 |
| 6 | Thiol peroxidase | S-oxy- | DB03382 |
| 7 | Levansucrase | Sucrose | DB02772 |
| 8 | Phospho-2-dehydro-3-deoxyheptonate aldolase | Phosphoenolpyruvate D-erythrose 4-phosphate | DB01819 DB03937 |
| 9 | ATP synthase F0F1 subunit alpha | Aurovertin B Piceatannol Quercetin Artenimol | DB07394 DB08399 DB04216 DB11638 |
| 10 | ATP synthase F0F1 subunit beta | Aurovertin B Piceatannol Quercetin Artenimol | DB07394 DB08399 DB04216 DB11638 |
| 11 | Glucosyltransferase-SI | Bezlotoxumab | DB13140 |
| 12 | Glucosyltransferase-I | Bezlotoxumab | DB13140 |
| 13 | Secreted antigen GbpB/SagA | Inebilizumab Blinatumomab Tisagenlecleucel | DB12530 DB09052 DB13881 |
| 14 | Formate acetyltransferase | OxamicAcid D-Treitol | DB03940 DB03278 |
| 15 | Fructose-1,6-biphosphate aldolase | Artenimol | DB11638 |
| 16 | Endolytic murein transglycosylase | Bicine | DB03709 |
| 17 | Oxamic Acid Artenimol | DB03940 DB11638 | |
| 18 | Ketol-acid reductoisomerase | Cocarboxylase | DB01987 |
| 19 | Aspartate-semialdehyde dehydrogenase | Nicotinamide adenine dinucleotide phosphate Aspartate Semialdehyde | DB03461 DB04498 |
| 20 | Enolase | Sodium fluoride | DB09325 |
| 21 | UDP-N-acetylglucosamine 1-carboxyvinyl-transferase 1 | Aminomethylcyclohexane 8-Anilinonaphthalene-1-sulfonic acid | DB02435 DB04474 |
| 22 | ATP-dependent protease ClpE | Bismuth subcitrate potassium | DB09275 |
Fig. 2Protein count for S. mutans MTCC 497 strain employing subtractive proteome analysis